Acute myelogenous leukemia is a disease in which the accumulation of primitive nonfunctional precursor cells results in the death of 80% of patients due to bleeding and infection. Although allogeneic bone marrow transplantation is curative, only 25% of AML patients are eligible for this therapy, and only half of these survive long term. Another 10-20% of patients are cured by combination chemotherapy. In order to develop new directions of therapy for AML, we are proposing to use cloned growth regulatory molecules to specifically sensitize the leukemia cells to phase specific agents. We will also use these growth factors to characterize the defects present in the subsets of AML which are associated with specific chromosomal translocations. We will use this information to identify targets for therapy in AML. The therapy will be based on growth factor therapy, combination chemotherapy, and bone marrow transplantation. These treatment programs will be linked to laboratory assays which will provide short-term molecular endpoints for the evaluation of response and minimal residual disease. We will classify patients with respect to a proliferative response or a differentiation induction response to a hematopoietic growth factor. We will compare in vitro with in vivo responses. We will compare proliferative responses in vitro and in vivo to growth factor induced changes in growth factor receptors, cytoplasmic signal transduction molecules, growth factor synthesis, intranuclear growth regulatory proteins (P53 and RB), early response gene expression, and killing of leukemic cells by phase specific agents and before and after exposure to myeloid growth factors. We will use PCR assays specific for each of the chromosomally defined subsets of AML to define response to therapy, response to growth factors and minimal residual disease. We will use this information to build sequential therapeutic programs which integrate chemotherapy with growth factors, used singly and in combinations. In this way, we hope to be able to develop therapy which is targeted to the molecular and biological defects in these diseases, which is less toxic to normal tissues and provides more durable remissions in all subsets of AML.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA055164-03
Application #
2096370
Study Section
Special Emphasis Panel (SRC (U2))
Project Start
1992-06-01
Project End
1996-03-31
Budget Start
1994-04-22
Budget End
1995-03-31
Support Year
3
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Other Basic Sciences
Type
Other Domestic Higher Education
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Ruvolo, Peter P; Ruvolo, Vivian R; Burks, Jared K et al. (2018) Role of MSC-derived galectin 3 in the AML microenvironment. Biochim Biophys Acta Mol Cell Res 1865:959-969
Ngankeu, Apollinaire; Ranganathan, Parvathi; Havelange, Violaine et al. (2018) Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget 9:4354-4365
Le, Phuong M; Andreeff, Michael; Battula, Venkata Lokesh (2018) Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis. Haematologica :
Jiang, Xuejie; Mak, Po Yee; Mu, Hong et al. (2018) Disruption of Wnt/?-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia. Clin Cancer Res 24:2417-2429
Ishizawa, Jo; Nakamaru, Kenji; Seki, Takahiko et al. (2018) Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Res 78:2721-2731
Sekihara, Kazumasa; Saitoh, Kaori; Han, Lina et al. (2017) Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1. Oncotarget 8:34552-34564
Carter, Bing Z; Mak, Po Yee; Wang, Xiangmeng et al. (2017) Focal Adhesion Kinase as a Potential Target in AML and MDS. Mol Cancer Ther 16:1133-1144
Zeng, Zhihong; Liu, Wenbin; Tsao, Twee et al. (2017) High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia. Haematologica 102:1537-1548
Pan, Rongqing; Ruvolo, Vivian; Mu, Hong et al. (2017) Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy. Cancer Cell 32:748-760.e6
Jacamo, Rodrigo; Davis, R Eric; Ling, Xiaoyang et al. (2017) Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia. Oncotarget 8:83354-83369

Showing the most recent 10 out of 422 publications